S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61

Atai Life Sciences Stock Forecast, Price & News

+0.20 (+1.79%)
(As of 12/8/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
263,317 shs
Average Volume
433,384 shs
Market Capitalization
$1.82 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ATAI News and Ratings via Email

Sign-up to receive the latest news and ratings for Atai Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Atai Life Sciences logo

About Atai Life Sciences

Atai Life Sciences N.V. focuses on operating as a holding company for ATAI Life Sciences AG that operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that are focused on multiple mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a GABA/nicotinic modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01 is a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.


ATAI Life Sciences N.V. Registered Shs hosts conference call for investors
November 11, 2021 |  markets.businessinsider.com
Analyst Ratings For ATAI Life Sciences
November 11, 2021 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$2.89 per share


Net Income
$-169.84 million
Pretax Margin




Free Float
Market Cap
$1.82 billion
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.11 out of 5 stars

Medical Sector

503rd out of 1,394 stocks

Pharmaceutical Preparations Industry

233rd out of 674 stocks

Analyst Opinion: 4.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Atai Life Sciences (NASDAQ:ATAI) Frequently Asked Questions

Is Atai Life Sciences a buy right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atai Life Sciences in the last year. There are currently 1 hold rating and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Atai Life Sciences stock.
View analyst ratings for Atai Life Sciences
or view top-rated stocks.

When is Atai Life Sciences' next earnings date?

Atai Life Sciences is scheduled to release its next quarterly earnings announcement on Monday, February 21st 2022.
View our earnings forecast for Atai Life Sciences

How were Atai Life Sciences' earnings last quarter?

Atai Life Sciences N.V. (NASDAQ:ATAI) issued its quarterly earnings data on Monday, November, 15th. The company reported ($0.21) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.28) by $0.07.
View Atai Life Sciences' earnings history

What price target have analysts set for ATAI?

14 Wall Street analysts have issued 12 month price targets for Atai Life Sciences' stock. Their forecasts range from $17.00 to $50.00. On average, they expect Atai Life Sciences' share price to reach $29.54 in the next year. This suggests a possible upside of 159.6% from the stock's current price.
View analysts' price targets for Atai Life Sciences
or view top-rated stocks among Wall Street analysts.

What other stocks do shareholders of Atai Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atai Life Sciences investors own include Alphabet (GOOG), Baidu (BIDU), Costco Wholesale (COST), MannKind (MNKD), NVIDIA (NVDA), Schlumberger (SLB), Twitter (TWTR), Adobe (ADBE), Allergan (AGN) and Achaogen (AKAO).

When did Atai Life Sciences IPO?

(ATAI) raised $200 million in an initial public offering on Friday, June 18th 2021. The company issued 14,300,000 shares at a price of $13.00-$15.00 per share. Credit Suisse, Citigroup, Cowen and Berenberg acted as the underwriters for the IPO and Cantor, RBC Capital Markets and Canaccord Genuity were co-managers.

What is Atai Life Sciences' stock symbol?

Atai Life Sciences trades on the NASDAQ under the ticker symbol "ATAI."

When does the company's lock-up period expire?

Atai Life Sciences' lock-up period expires on Wednesday, December 15th. Atai Life Sciences had issued 15,000,000 shares in its public offering on June 18th. The total size of the offering was $225,000,000 based on an initial share price of $15.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the end of the lock-up period.

Who are Atai Life Sciences' major shareholders?

Atai Life Sciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Falcon Edge Capital LP (1.66%), Morgan Stanley (0.64%), Pura Vida Investments LLC (0.00%), Millennium Management LLC (0.32%), Rock Springs Capital Management LP (0.21%) and Healthcare of Ontario Pension Plan Trust Fund (0.16%). Company insiders that own Atai Life Sciences stock include Apeiron Investment Group Ltd, Christian Angermayer, Gregory L Weaver and Srinivas Rao.

Which institutional investors are selling Atai Life Sciences stock?

ATAI stock was sold by a variety of institutional investors in the last quarter, including Element Capital Management LLC, Healthcare of Ontario Pension Plan Trust Fund, Falcon Edge Capital LP, Morgan Stanley, Millennium Management LLC, and Squarepoint Ops LLC.

Which institutional investors are buying Atai Life Sciences stock?

ATAI stock was bought by a variety of institutional investors in the last quarter, including Pura Vida Investments LLC, Citigroup Inc., Citadel Advisors LLC, Caption Management LLC, Penserra Capital Management LLC, Cubist Systematic Strategies LLC, Allianz Asset Management GmbH, and AdvisorShares Investments LLC. Company insiders that have bought Atai Life Sciences stock in the last two years include Apeiron Investment Group Ltd, Christian Angermayer, Gregory L Weaver, and Srinivas Rao.

How do I buy shares of Atai Life Sciences?

Shares of ATAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Atai Life Sciences' stock price today?

One share of ATAI stock can currently be purchased for approximately $11.38.

How much money does Atai Life Sciences make?

Atai Life Sciences has a market capitalization of $1.82 billion.

How many employees does Atai Life Sciences have?

Atai Life Sciences employs 35 workers across the globe.

What is Atai Life Sciences' official website?

The official website for Atai Life Sciences is www.atai.net.cn.

Where are Atai Life Sciences' headquarters?

Atai Life Sciences is headquartered at c/o Mindspace Krausenstra sse 9-10, Berlin, Berlin 10117.

How can I contact Atai Life Sciences?

Atai Life Sciences' mailing address is c/o Mindspace Krausenstra sse 9-10, Berlin, Berlin 10117. The company can be reached via email at [email protected].

This page was last updated on 12/9/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.